
Explore the depths
of NSAID efficacy.
Nevanac™
(nepafenac ophthalmic
suspension) 0.1%
Deep Performance.



NEVANAC™ ophthalmic suspension is contraindicated in patients with previously de
The most frequently reported adverse events following cataract surgery were
pressure, and sticky sensation. These events occurred in approximately 5%

NEVANAC™ suspension provides highly effective post-cataract inflammation control[2]



- >80% experienced clinical cures without use of steroids[2]
- Superior efficacy in both early and late postoperative periods

Results are from a prospective, double-blind, randomized, vehicle-controlled study of 476 patients randomized to vehicle or NEVANAC™ suspension 1 drop TID for 16 days, starting 1 day presurgery. Clinical cure = 0 flare plus 0-5 cells.

NEVANAC™ suspension delivers superior prostaglandin inhibition[3]



- NSAIDs reduce the development of inflammation through their specific ability to inhibit prostaglandins
- Administration of nepafenac 0.1% suspension leads to significant suppression of PGE_2 synthesis in the posterior portion of the eye[3†]

†*Studies conducted in animals.*

onstrated hypersensitivity to any of the ingredients in the formulation or to other NSAIDs.
osular opacity, decreased visual acuity, foreign body sensation, increased intraocular
10% of patients and may be the consequence of the cataract surgical procedure.

Nevanac™
(nepafenac ophthalmic suspension) 0.1%

Deep Performance.

NEVANAC™ Suspension: Performance Meets Proven Safety and Tolerability

- Excellent safety profile with minimal systemic absorption[4]
- The excellent safety of NEVANAC™ suspension has been demonstrated *in vivo** at concentrations up to 1.5%, dosing regimens up to 8 drops daily, and at periods up to 6 months[5-7]
- Proven safe and well tolerated throughout *in vivo** ocular tissues with no delays in wound healing[5-7]
- Overall adverse event profile similar to vehicle[4,8,9]
- No ocular burning or stinging related to treatment reported in pivotal clinical trials[4,8,9]
- Convenient TID dosing[4]

Prescribe NEVANAC™ suspension for excellent postoperative pain and inflammation control.

NEVANAC™ ophthalmic suspension is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation or to other NSAIDs. The most frequently reported adverse events following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These events occurred in approximately 5% to 10% of patients and may be the consequence of the cataract surgical procedure.

*Studies conducted in animals.

References:

1. Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation, II: in vitro bioactivation and permeation of external ocular barriers. *Inflammation.* 2000;24:371-384.
2. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of Nepafenac. Accepted for publication: *Curr Med Res Opin.*
3. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. *Inflammation.* 2003;27:295-305.
4. NEVANAC™ suspension prescribing information.
5. Walker LM, Rice RL, Heaton JD, Hackett RB, Munger RJ, Hiddemen JW. Ocular effects of nepafenac ophthalmic suspension following three months of topical ocular administration to cynomolgus monkeys. Paper presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 3, 2005; Fort Lauderdale, Fla.
6. Heaton J, Hiddemen JW, Hackett RB, Rice RL, Gruebbel MM. Ocular effects of nepafenac ophthalmic suspension following six months of topical ocular administration to pigmented rabbits. Paper presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 3, 2005; Fort Lauderdale, Fla.
7. McGee DH, Heaton JD, Gruebbel MM, Hackett RB, Rice RL, Hiddemen JW. Ocular effects of nepafenac ophthalmic suspension in New Zealand white rabbits undergoing partial corneal incisions. Paper presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 3, 2005; Fort Lauderdale, Fla.
8. Lane SS, Modi SS, Holland EJ, et al. Nepafenac ophthalmic suspension 0.1% before and after surgery for postoperative anterior segment inflammation. Paper presented at: American Society of Cataract and Refractive Surgery; April 19, 2005; Washington, DC.
9. Data on file. Alcon Laboratories, Inc. 2005.

Alcon®
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134
www.alcon.com

www.nevanac.com

 1/06 NPF06500VS

Deep Performance.